Cross Country Healthcare, Inc. (CCRN)
NASDAQHealth CareStaffing & Employment ServicesSnapshot 2026-09-04
$13.250.00%
Close 2026-07-27 · 1-day change
NASDAQHealth CareStaffing & Employment ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Adjusted EPS better than $(0.06) in Q1 2026: Adj EPS guidance -6.0% to -4.0% vs -6.0% target.
Cross Country Healthcare is growing revenue near $240 million in Q1 2026. The company completed an acquisition to expand its workforce platform. Analysts expect earnings per share to improve to $0.09 in 2026. The stock price is down about 47%, reflecting challenges but also potential upside.
The company is still loss-making and missed EPS guidance in Q1 2026 with $(0.14) reported. Management has had volatile execution and key executives departed recently. Revenue growth is slow at about 1.5% expected next year. Litigation and integration risks from the merger remain.
The market price reflects about 1.5% revenue growth and continued losses. It discounts significant risks from volatile management and recent earnings misses. Our view sees potential for modest earnings improvement but also ongoing challenges.
Breaks if: Adjusted EPS falls below $(0.06) in Q1 2026
Provide adjusted EPS guidance for Q1 2026 and manage to results within the guided range.
Newly stated in 2026-Q1. Management guided adjusted EPS between $(0.06) and $(0.04) and reported adjusted EPS of $(0.03), outperforming the guidance range. This indicates delivery on the adjusted EPS guidance priority for the quarter.
“Adjusted EPS guidance $(0.06) - $(0.04); actual adjusted EPS $(0.03) better than guidance.”
Breaks if: Revenue falls below $235 million in Q1 2026
Provide revenue guidance for the first quarter of 2026 and achieve results within or above the guided range.
Newly stated in 2026-Q1. Management guided revenue for Q1 2026 between $235 million and $240 million and actual revenue was $241.1 million, slightly exceeding guidance. This shows delivery on the revenue guidance priority for the quarter.
“Q1 2026 Range Revenue $235 million - $240 million; actual revenue $241.1 million exceeded guidance.”
Breaks if: Material setbacks or delays in merger integration reported
Complete the merger with KL Criss Cross and transition to private ownership to enable growth and operational focus.
Stated as a priority in 2 disclosures including 2026-Q1 and the 2026-07-27 press release. The merger with KL Criss Cross was completed on 2026-07-27, resulting in the company becoming a wholly owned subsidiary and delisting from Nasdaq. This marks a strategic shift to private ownership, consistent with management's stated goal to enable growth and operational focus.
“On May 6, 2026, the Company entered into an Agreement and Plan of Merger with KL Criss Cross Intermediate, LLC.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation with a focus on recovery after recent struggles. The current thesis state is cautious, as management has shown volatility and recent financial performance has been weak.
The market appears to be pricing in a low level of confidence, reflecting the company's recent struggles compared to peers. Valuation suggests that CCRN is considered cheap relative to its competitors, but there is an expectations gap indicating that the market anticipates further challenges.
Fundamentals may remain under pressure in the near term due to high risk and weak recent performance. However, management's ability to meet revenue and adjusted EPS guidance could provide some stability.
The long-term thesis hinges on management's execution of strategic priorities, particularly the recent merger and its impact on growth. Additionally, broader sector performance, especially from major healthcare players, will be crucial in shaping CCRN's trajectory.
Over the next 1 to 3 years, CCRN's performance will depend on management's ability to navigate challenges and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.